可穿戴活动追踪器与结构化反馈项目对血液透析患者体力活动的影响:Step4Life 先导随机对照试验
该先导随机对照试验纳入55例血液透析的终末期肾病患者,1:1随机分为可穿戴活动追踪器加结构化反馈组与单用可穿戴活动追踪器组,干预12周。结果显示结构化反馈组每日步数变化大于单用追踪器组,组间差异有统计学意义;作者认为需进一步研究长期可持续性与健康获益。
要点
- 在血液透析患者中,可穿戴活动追踪器联合结构化反馈较单用追踪器使12周每日步数增加更多。
- 46例完成12周干预,两组各23例;两组基线步数和其他特征均衡。
- 作者指出需进一步研究该干预的长期可持续性和潜在健康获益。
核心结论
- 该先导随机对照试验表明,与单用可穿戴活动追踪器相比,结构化反馈联合可穿戴活动追踪器使每日步数增加更多,并在12周内维持。
- 作者指出未来需进一步研究该干预的长期可持续性和血液透析患者的潜在健康获益。
研究设计与样本
- 随机对照试验,纳入55例来自单一学术血液透析中心、能够行走(使用或不使用辅助设备)的终末期肾病血液透析患者,招募时间为2019年1月至2020年4月。
- 所有参与者佩戴Fitbit Charge 2追踪器至少12周,按1:1随机分为可穿戴活动追踪器加结构化反馈组与单用可穿戴活动追踪器组;结构化反馈组每周接受随机化后步数反馈咨询。
- 主要分析为意向性治疗分析,采用混合效应线性回归评估两组从基线至12周每日步数变化。
主要发现
- 55例中46例完成12周干预(每组23例);平均年龄62(±14 SD)岁,44%为黑人,36%为西班牙裔。
- 基线步数:结构化反馈干预组3704(1594)步 vs 单用可穿戴活动追踪器组3808(1890)步,两组其他特征均衡。
- 12周时每日步数变化:结构化反馈组Δ920(±580 SD)步 vs 单用追踪器组Δ281(±186 SD)步;组间差异Δ639(±538 SD)步,P<0.05。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 单中心研究。
- 样本量小。
- 作者指出未来需进一步研究该干预的长期可持续性和潜在健康获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: People with end-stage kidney disease (ESKD) have very low physical activity, and the degree of inactivity is strongly associated with morbidity and mortality. We assessed the feasibility and effectiveness of a 12-week intervention coupling a wearable activity tracker (FitBit) and structured feedback coaching versus wearable activity tracker alone on changes in physical activity in hemodialysis patients. STUDY DESIGN: Randomized controlled trial. SETTING & PARTICIPANTS: 55 participants with ESKD receiving hemodialysis who were able to walk with or without assistive devices recruited from a single academic hemodialysis unit between January 2019 and April 2020. INTERVENTIONS: All participants wore a Fitbit Charge 2 tracker for a minimum of 12 weeks. Participants were randomly assigned 1:1 to a wearable activity tracker plus a structured feedback intervention versus the wearable activity tracker alone. The structured feedback group was counseled weekly on steps achieved after randomization. OUTCOME: The outcome was step count, and the main parameter of interest was the absolute change in daily step count, averaged per week, from baseline to completion of 12 weeks intervention. In the intention-to-treat analysis, mixed-effect linear regression analysis was used to evaluate change in daily step count from baseline to 12-weeks in both arms. RESULTS: Out of 55 participants, 46 participants completed the 12-week intervention (23 per arm). The mean age was 62 (± 14 SD) years; 44% were Black, and 36% were Hispanic. At baseline, step count (structured feedback intervention: 3,704 [1,594] vs wearable activity tracker alone: 3,808 [1,890]) and other participant characteristics were balanced between the arms. We observed a larger change in daily step count in the structured feedback arm at 12 weeks relative to use of the wearable activity tracker alone arm (Δ 920 [±580 SD] versus Δ 281 [±186 SD] steps; between-group difference Δ 639 [±538 SD] steps; P<0.05). LIMITATIONS: Single-center study and small sample size. CONCLUSION: This pilot randomized controlled trial demonstrated that structured feedback coupled with a wearable activity tracker led to a greater daily step count that was sustained over 12 weeks relative to a wearable activity tracker alone. Future studies are required to determine longer-term sustainability of the intervention and potential health benefits in hemodialysis patients. FUNDING: Grants from industry (Satellite Healthcare) and government (National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK). TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT05241171.
引用
- Malhotra R, Rahimi S, Agarwal U, et al. The Impact of a Wearable Activity Tracker and Structured Feedback Program on Physical Activity in Hemodialysis Patients: The Step4Life Pilot Randomized Controlled Trial. Am J Kidney Dis. 2023. PMID: 36801430. doi:10.1053/j.ajkd.2022.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。